Age, ethnicity, and survival rates by time period. (A) Age, ethnicity and 3-year overall survival before and after the advent of gemcitabine/cisplatin; (B) age, ethnicity and 3-year cholangiocarcinoma-specific survival before and after the advent of gemcitabine/cisplatin. NH, non-Hispanic; W, Whites; B, Blacks; A/PI, Asian/Pacific Islander; AI/AN, American Indian/Alaska Native; H, Hispanic; N/A, not available.